Seed Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
27
- Latest Deal Type
-
Series A3
- Latest Deal Amount
-
$30M
- Investors
-
3
Seed Therapeutics General Information
Description
Operator of a biotechnology company intended to develop targeted protein degradation therapeutics for diseases with limited treatment options. The company specializes in research and development and is engaged in harnessing and engineering molecules that use molecular glues to attack protein targets, enabling the oncology and neurodegeneration sectors to tackle previously undruggable diseases with novel drug candidates.
Contact Information
Website
www.seedtherapeutics.comCorporate Office
- 411 Swedeland Road
- Suite 1000
- King of Prussia, PA 19406
- United States
Corporate Office
- 411 Swedeland Road
- Suite 1000
- King of Prussia, PA 19406
- United States
Seed Therapeutics Timeline
Seed Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series A3) | 01-Aug-2025 | $30M | Completed | Clinical Trials - General | ||
| 4. Secondary Transaction - Private | 28-Jan-2025 | Completed | Clinical Trials - General | |||
| 3. Accelerator/Incubator | 10-Oct-2024 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series A1) | $20M | Completed | Clinical Trials - General | |||
| 1. Corporate | 12-Nov-2020 | $20M | $20M | Completed | Clinical Trials - General |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Seed Therapeutics Patents
Seed Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026101959-A1 | Heteroaromatic indolesulfonamides | Pending | 06-Nov-2024 | ||
| WO-2025189015-A1 | Heteroaromatic indolesulfonamides | Pending | 07-Mar-2024 | ||
| WO-2025189015-A8 | Heteroaromatic indolesulfonamides | Pending | 07-Mar-2024 | ||
| AU-2024265472-A1 | Heteroaromatic indolesulfonamides | Pending | 01-May-2023 | ||
| EP-4704836-A1 | Heteroaromatic indolesulfonamides | Pending | 01-May-2023 | C07D417/12 |
Seed Therapeutics Signals
Seed Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Eisai | Corporate Venture Capital | Minority | ||
| Endless Frontier Labs | Accelerator/Incubator | |||
| Lilly USA | Corporation | Minority |
Seed Therapeutics FAQs
-
When was Seed Therapeutics founded?
Seed Therapeutics was founded in 2019.
-
Where is Seed Therapeutics headquartered?
Seed Therapeutics is headquartered in King of Prussia, PA.
-
What is the size of Seed Therapeutics?
Seed Therapeutics has 27 total employees.
-
What industry is Seed Therapeutics in?
Seed Therapeutics’s primary industry is Drug Discovery.
-
Is Seed Therapeutics a private or public company?
Seed Therapeutics is a Private company.
-
What is the current valuation of Seed Therapeutics?
The current valuation of Seed Therapeutics is .
-
What is Seed Therapeutics’s current revenue?
The current revenue for Seed Therapeutics is .
-
How much funding has Seed Therapeutics raised over time?
Seed Therapeutics has raised $50M.
-
Who are Seed Therapeutics’s investors?
Eisai, Endless Frontier Labs, and Lilly USA have invested in Seed Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process